Research Analysts Set Expectations for CorMedix Q3 Earnings

Key Points

• HC Wainwright raised CorMedix’s Q3 2026 EPS estimate to a loss of $0.05 per share from a prior forecasted loss of $0.08. The firm expects losses of $0.08 in Q4 2026, followed by earnings of $0.14 in FY2027 and $0.54 in FY2028.
• CorMedix reported quarterly EPS of $0.29, exceeding the $0.24 consensus estimate, while revenue of $101.93 million topped expectations of $96.04 million.
• Analyst sentiment remains favorable, with six Buy ratings and two Holds producing a “Moderate Buy” consensus and an average price target of $15, well above the stock’s reported $7.67 opening price.

CorMedix Inc (NASDAQ:CRMD - Free Report) - Investment analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for CorMedix in a note issued to investors on Friday, August 14th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($0.05) for the quarter, up from their prior estimate of ($0.08). The consensus estimate for CorMedix's current full-year earnings is $0.54 per share. HC Wainwright also issued estimates for CorMedix's Q4 2026 earnings at ($0.08) EPS, FY2027 earnings at $0.14 EPS and FY2028 earnings at $0.54 EPS.

CRMD has been the subject of several other research reports. Royal Bank Of Canada raised their price target on shares of CorMedix from $13.00 to $14.00 and gave the stock an "outperform" rating in a report on Friday. Needham & Company LLC lifted their target price on shares of CorMedix from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Monday, April 27th. D. Boral Capital restated a "buy" rating and set a $14.00 target price on shares of CorMedix in a research report on Monday, April 27th. Zacks Research raised CorMedix from a "strong sell" rating to a "hold" rating in a research note on Friday, May 15th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of CorMedix in a report on Tuesday, August 11th. Six investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $15.00.

CorMedix Trading Up 1.7%

NASDAQ CRMD opened at $7.67 on Tuesday. The firm has a market capitalization of $597.80 million, a PE ratio of 3.58 and a beta of 1.50. The business's 50-day moving average price is $8.12 and its two-hundred day moving average price is $7.64. The company has a current ratio of 2.56, a quick ratio of 2.36 and a debt-to-equity ratio of 0.31. CorMedix has a 12 month low of $6.13 and a 12 month high of $14.96.

CorMedix (NASDAQ:CRMD - Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported $0.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.24 by $0.05. The firm had revenue of $101.93 million during the quarter, compared to analysts' expectations of $96.04 million. CorMedix had a net margin of 40.49% and a return on equity of 40.52%.

Institutional Investors Weigh In On CorMedix

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empowered Funds LLC acquired a new position in shares of CorMedix during the second quarter worth approximately $1,909,000. Hayek Kallen Investment Management bought a new position in shares of CorMedix in the second quarter valued at $123,000. Corient Private Wealth LP acquired a new position in shares of CorMedix during the second quarter valued at about $755,000. Bank of America Corp DE acquired a new position in shares of CorMedix during the second quarter valued at about $1,183,000. Finally, Freestone Grove Partners LP acquired a new stake in shares of CorMedix in the 2nd quarter worth about $262,000. Institutional investors own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company's lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source